Globe editors have posted this research report with permission of Thomson Reuters I/B/E/S. This should not be construed as an endorsement of the report’s recommendations. For more on The Globe’s disclaimers please read here. The following is excerpted from the report:

Earnings highlights

Q1 2018 Y/Y Blended Earnings Growth Estimates

  • TSX Composite (TXCX) = 11.9 per cent
  • Ex-energy = 14.0 per cent
  • Valeant Pharmaceuticals International Inc. (VRX-T) = 6.5 per cent
  • Healthcare ex-VRX = 49.2 per cent
  • TSX Composite ex-VRX = 12.0 per cent

Q1 2018 Performance vs. Earnings Expectations

Eighty-one per cent of the TSX Composite companies have reported Q1 2018 EPS. Of the 198 companies in the index that have reported earnings to date for Q1 2018:

  • 42.4 per cent reported above analyst expectations
  • 41.9 per cent reported below analyst expectations

Revenue highlights

Q1 2018 Y/Y Blended Revenue Growth Estimates:

  • TSX Composite = 9.4 per cent
  • Ex-energy = 7.1 per cent
  • Valeant = -10.7 per cent
  • Healthcare ex-Valeant = 8.5 per cent
  • TSX Composite ex-Valeant = 9.6 per cent

Q1 2018 Performance vs. Revenue Expectations:

Of the TSX Composite companies that have reported revenue to date for Q1 2018:

Story continues below advertisement

  • 58.1 per cent reported above analyst expectations
  • 41.9 per cent reported below analyst expectations

Read the full report here.

Read other research reports here